Osteoprotegerin is an early marker of the fibrotic process and of antifibrotic treatment responses in ex vivo lung fibrosis
Kurnia S.S. Putri,
Adhyatmika Adhyatmika,
Carian E. Boorsma
et al.
Abstract:Background
Lung fibrosis is a chronic lung disease with a high mortality rate with only two approved drugs (pirfenidone and nintedanib) to attenuate its progression. To date there are no reliable biomarkers to assess fibrosis development and/or treatment effects for these two drugs. Osteoprotegerin (OPG) is used as a serum marker to diagnose liver fibrosis and we have previously shown it associates with lung fibrosis as well.
Methods
Here we used murine and human precision-cut lung slices to investigate the … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.